Therapeutic compounds

1. A compound of formula I:

wherein:

A is (C 6 -C 12 )aryl or aryl(C 1 -C 4 )alkyl- wherein any aryl or aryl(C 1 -C 4 )alkyl- of A is optionally substituted with 1, 2, 3, 4 or 5 Z 1 groups;

B is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl of B has 2-10 carbon atoms and 1-5 heteroatoms selected from oxygen, nitrogen, and sulfur, and is optionally substituted with 1, 2, 3, 4 or 5 Z 2 groups, and wherein Q and W are connected to adjacent ring atoms of B;

C is phenyl, 5-membered heteroaryl or 6-membered heteroaryl, wherein any phenyl, 5-membered heteroaryl or 6-membered heteroaryl of C is optionally substituted with 1, 2, 3, or 4 Z 3 groups, and wherein the 5-membered heteroaryl or 6-membered heteroaryl of C has 1-6 carbon atoms and 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur, and is monocyclic, and wherein Q and Y are connected to adjacent ring atoms of C, or Q and Y are connected to the first and third atom of three consecutive ring atoms of C;

each Q is independently selected from —C(R 2a ) 2 —, —O—, —NR 1a —, —S—, —C(═O)—, —S(═O)— and —S(═O) 2 —, or two adjacent Q groups taken together can be —CR 2b ═CR 2b —;

W is —CH 2 —;

X is CH or N;

Y is —CH 2 —;

n is 1, 2, 3, 4 or 5;

R 1 is selected from (C 1 -C 6 )alkyl, (C 3 -C 7 )carbocycle, and (C 3 -C 7 )carbocycle(C 1 -C 6 )alkyl;

R 1a is H or (C 1 -C 4 )alkyl, each R 2a is independently H, halogen or (C 1 -C 4 )alkyl, and each R 2b is independently H or (C 1 -C 4 )alkyl, or one R 2a together with an adjacent Q group forms a three membered carbocycle;

each Z 1 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, halogen, —CN, —OR n1 , —OC(O)R p1 , —OC(O)NR q1 R r1 , —SR n1 , —S(O)R p1 , —S(O) 2 OH, —S(O) 2 R p1 , —S(O) 2 NR q1 R r1 , —NR q1 R r1 , —NR n1 COR p1 , —NR n1 CO 2 R p1 , —NR n1 CONR q1 , —NR n1 S(O) 2 R p1 , —NR n1 S(O) 2 OR p1 , —NR n1 S(O) 2 NR q1 OR r1 , NO 2 , —C(O)R n1 , —C(O)OR n1 and —C(O)NR q1 R r1 , wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of Z 1 is optionally substituted with 1, 2, 3, 4 or 5 Z 1a groups;

each Z 1a is independently selected from halogen, —CN, —OR n2 , —OC(O)R p2 , —OC(O)NR q2 R r2 , —SR n2 , (O)R p2 , —S(O) 2 OH, (O) 2 R p2 , (O) 2 NR q2 R r2 , —NR q2 R r2 , —NR n2 COR p2 , —NR n2 CO 2 R p2 , —NR n2 CONR q2 R r2 , —NR n2 S(O) 2 R p2 , —NR n2 S(O) 2 OR p2 , —NR n2 S(O) 2 NR q2 R r2 , NO 2 , —C(O)R n2 , —C(O)OR n2 and —C(O)NR q2 R r2 ;

each Z 1b is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl;

each R p1 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R n1 is optionally substituted with 1, 2, 3, 4 or 5 Z 1a groups;

each R p1 is independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R p1 is optionally substituted with 1, 2, 3, 4 or 5 Z 1a groups;

R q1 and R r1 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R q1 or R r1 is optionally substituted with 1, 2, 3, 4 or 5 Z 1a groups, or R q1 and R r1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle has 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur and is optionally substituted with 1, 2, 3, 4 or 5 Z 1a or Z 1b groups;

each R n2 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )haloalkyl;

each R p1 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )haloalkyl;

R q2 and R r2 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )haloalkyl, or R q2 and R r2 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle wherein the 5, 6 or 7-membered heterocycle has 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur;

each Z 2 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, halogen, —CN, —OR n3 , —OC(O)R p3 , —OC(O)NR q3 R r3 , —SR n3 , —S(O)R p3 , —S(O) 2 OH, —S(O) 2 R p3 , —S(O) 2 NR q3 R r3 , —NR q3 R r3 , —NR n3 COR p3 , —NR n3 CO 2 R p3 , —NR n3 CONR q3 R r3 , —NR n3 S(O) 2 R p3 , —NR n3 S(O) 2 OR p3 , —NR n3 S(O) 2 NR q3 R r3 , NO 2 , —C(O)R n3 , —C(O)OR n3 and —C(O)NR q3 R r3 , wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of Z 2 is optionally substituted with 1, 2, 3, 4 or 5 Z 2a groups;

each Z 2a is independently selected from halogen, —CN, —OR n4 , —OC(O)R p4 , —OC(O)NR q4 R r4 , —SR n4 , —S(O)R p4 , —S(O) 2 OH, —S(O) 2 R p4 , —S(O) 2 NR q4 R r4 , —NR q4 R r4 , —NR n4 COR p4 , —NR n4 CO 2 R p4 , —NR n4 CONR q4 R r4 , —NR n4 S(O) 2 R p4 , —NR n4 S(O) 2 OR p4 , —NR n4 S(O) 2 NR q4 R r4 , NO 2 , —C(O)R n4 , —C(O)OR n4 and —C(O)NR q4 R r4 ;

each Z 2b is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl and (C 2 -C 4 )alkynyl;

each R n3 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R n3 is optionally substituted with 1, 2, 3, 4 or 5 Z 2a groups;

each R p3 is independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R p3 is optionally substituted with 1, 2, 3, 4 or 5 Z 2a groups;

R q3 and R r3 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, wherein any (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl of R q3 or R r3 is optionally substituted with 1, 2, 3, 4 or 5 Z 2a groups, or R q3 and R r3 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle has 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur is optionally substituted with 1, 2, 3, 4 or 5 Z 2a or Z 2b groups;

each R n4 is independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 3 -C 7 )carbocycle, and (C 1 -C 4 )haloalkyl;

each R p4 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 3 -C 7 )carbocycle, and (C 1 -C 4 )haloalkyl;

R q4 and R r4 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -C 7 )carbocycle, and (C 1 -C 4 )haloalkyl, or R q4 and R r4 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle wherein the 5, 6 or 7-membered heterocycle has 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur;

each Z 3 is independently selected from (C 1 -C 4 )alkyl, halogen, —CN, —OR n5 , —NR n5 COR p5 , —C(O)R n5 , and —C(O)NR q5 R r5 ;

each R n5 is independently selected from H, (C 1 -C 4 )alkyl, and (C 1 -C 4 )haloalkyl;

each R p5 is independently selected from (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )haloalkyl; and

R q5 and R r5 are each independently selected from H, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )haloalkyl, or R q5 and R r5 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle wherein the 5, 6 or 7-membered heterocycle has 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Q is independently selected from —CH 2 —S— and —S(═O) 2 —, or two adjacent Q groups taken together are —CH═CH—.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 2, 3 or 4.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Q n is —CH═CHCH 2 —, —(CH 2 ) 2 —, —(CH 2 ) 3 —, —(CH 2 ) 4 —, —CH 2 CH═CH—, —CH 2 SCH 2 —, —CH 2 S(═O) 2 CH 2 —, —CH═CH—, —CH 2 S(CH 2 ) 2 —, —CH 2 S(═O) 2 (CH 2 ) 2 —, —CH 2 S—, —CH 2 S(═O) 2 —, —SCH 2 — or —S(═O) 2 CH 2 —.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is CH.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein C is phenyl, 5-membered heteroaryl or 6-membered heteroaryl, wherein any phenyl, 5-membered heteroaryl or 6-membered heteroaryl of C is optionally substituted with 1, 2, 3, or 4 Z 3 groups, and wherein Q and Y are connected to adjacent ring atoms of C.

7. The compound of claim 1 which is a compound of formula Ic:

wherein phenyl C is optionally substituted with 1, 2, 3, or 4 Z 3 groups, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Z 3 is fluoro.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is (C 1 -C 4 )alkyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Z 1 is independently selected from halogen and —O(C 1 -C 4 )alkyl.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is 4-methoxyphenyl, 4-chlorophenyl or benzyl.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein B is bicyclic-heteroaryl, wherein the bicyclic-heteroaryl has 2-10 carbon atoms and 1-5 heteroatoms and is optionally substituted with 1, 2, 3, 4 or 5 Z 2 groups.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Z 2 is independently selected from (C 1 -C 4 )alkyl, halogen, —OH and —O(C 1 -C 4 )alkyl, wherein (C 1 -C 4 )alkyl is optionally substituted with 1, 2, 3, 4 or 5 halogen.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein B is selected from:

wherein the wavy lines denote points of attachment of B to W and Q of the compound of formula I.

15. The compound of claim 1 selected from

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17. A method for treating an HIV infection in a mammal comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the mammal.